FY2026 EPS Estimates for OTCMKTS:MDNAF Lowered by Analyst

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of Medicenna Therapeutics in a note issued to investors on Tuesday, February 17th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.18) per share for the year, down from their previous forecast of ($0.17). HC Wainwright also issued estimates for Medicenna Therapeutics’ Q4 2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.12) EPS and FY2029 earnings at $0.10 EPS.

Separately, Zacks Research cut Medicenna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Medicenna Therapeutics Trading Up 4.1%

MDNAF stock opened at $0.66 on Thursday. The firm has a market capitalization of $55.05 million, a price-to-earnings ratio of -6.00 and a beta of 1.81. Medicenna Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.43.

Medicenna Therapeutics (OTCMKTS:MDNAF) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Key Medicenna Therapeutics News

Here are the key news stories impacting Medicenna Therapeutics this week:

• Positive Sentiment: HC Wainwright still models a return to positive EPS by FY2029 (EPS $0.10), indicating a path to long‑term profitability even after cuts. HC Wainwright estimates (summary)
• Negative Sentiment: Zacks Research downgraded Medicenna from “strong‑buy” to “hold” — a sentiment downgrade that can reduce buy‑side interest and weigh on the stock. Zacks downgrade
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions to near‑term and medium‑term EPS (multiple quarters in 2026–2027 and FY2026–FY2028 were reduced), increasing the view of larger near‑term losses and extended cash burn. Key cuts include FY2027 EPS to ($0.22) (from ($0.15)) and FY2028 to ($0.12) (from ($0.04)). HC Wainwright cuts (summary)
• Negative Sentiment: HC Wainwright reportedly lowered a FY2030 EPS forecast as well, signaling longer-term estimate reductions beyond FY2029. This suggests the firm expects a slower recovery to consistent profitability. FY2030 EPS cut article

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.